Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort

Catheterization and Cardiovascular Interventions

Volumn 71, Issue 6, 2008, Pages 764-769

  Vlaar, Pieter J ^a,b   Rihal, Charanjit S ^a   Singh, Mandeep ^a   Lennon, Ryan ^a   Ting, Henry H ^a   Bresnahan, John F ^a   Holmes Jr , David R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; RSTN, restenosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVASCULARIZATION; ST SEGMENT ELEVATION; STENT; SURVIVAL; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; MINNESOTA; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT READMISSION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RECURRENCE; REGISTRIES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 43249130898     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21479     Document Type: Article

References (19)

1. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 2005;26:1262-1268.
2. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, Cutlip DE, Kuntz RE, Moses JW. Two-year outcomes after sirolimus-eluting stent implantation: Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006;47:1350-1355.
3. Grube E, Silber S, Hauptmann KE, Buellesfeld L, Mueller R, Lim V, Gerekens U, Russell ME. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 2005;96:79-82.
4. Diaz de la Liera LS, Ballesteros S, Nevado J, Fernandez M, Villa M, Sanchez A, Retegui G, Garcia D, Martinez A. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007; 154:164-166.
5. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R,STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117.
6. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-1930.
7. Stone GW, Moses JW, Ellis SG Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
8. Hofma SH, Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, Regar E, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, Van Domburg RT, Serruys PW. One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart 2005;91:1176-1180.
9. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, Hoye A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-708.
10. Newell MC, Henry CR, Sigakis CJ, Unger BT, Larson DM, Chavez IJ, Burke MN, Traverse JH, Henry TD. Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006;97:1299-1302.
11. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113.
12. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C,TYPHOON Investigators. Sirolimus-eluting versus uncoated Stents in acute myocardial infarction. N Engl J Med 2006;355:1093-1104.
13. Singh M, Rihal CS, Lennon RJ, Spertus J, Rumsfeld JS, Holmes DR Jr. Bedside estimation of risk from percutaneous coronary intervention: The new Mayo Clinic risk scores. Mayo Clin Proc 2007;82:701-708.
14. Tanimoto S, Tsuchida K, Daemen J, Boersma E. Drug-eluting stent implantation in acute myocardial infarction. Do we need another randomized trial? Eurolnterv 2006;2:23-27.
15. Pasceri V, Patti G, Special G, Pristipino C, Richichi G, Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 2007;153:749-754.
16. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T, Virmani R. Images in cardiovascular medicine: Sirolimus-eluting stent implanted in human coronary artery for 16 months: Pathological findings. Circulation 2003;107:1340-1341.
17. Suzuki T, Kopia G, Hayahi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
18. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998;13:3153-3159.
19. Virmani R. Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.